Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
As Celltrion Also Submits Phase III Interchangeable Humira Data
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
You may also be interested in...
Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.
As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.